Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay J Mathew

Showing results (121-130 of 190) with videos related to

Pageof 19
Sort By:
Annals of the New York Academy of Sciences|August 8, 2006
Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrationsJeremy D Coplan, Eric L P Smith, Margaret Altemus, et al.
The Journal of Clinical Psychiatry|October 2, 2014
Ketamine safety and tolerability in clinical trials for treatment-resistant depressionLe-Ben Wan, Cara F Levitch, Andrew M Perez, et al.
Chronic Stress (Thousand Oaks, Calif.)|July 3, 2018
Early Life Stress Associated With Increased Striatal <i>N</i>-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral CorrelatesJeremy D Coplan, Dunyue Lu, Alexander M El Sehamy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2014
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trialJames W Murrough, Katherine E Burdick, Cara F Levitch, et al.
The American Journal of Psychiatry|June 25, 2019
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical TrialElias Dakwar, Edward V Nunes, Carl L Hart, et al.
Biological Psychiatry|July 31, 2012
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depressionJames W Murrough, Andrew M Perez, Sarah Pillemer, et al.
Depression and Anxiety|July 13, 2021
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trialNithya Ramakrishnan, Marijn Lijffijt, Charles E Green, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|August 28, 2024
Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-AnalysisSandesh Reddy, Katherine E Kabotyanski, Samad Hirani, et al.
Journal of Affective Disorders|October 27, 2022
Replication of distinct trajectories of antidepressant response to intravenous ketamineBrittany O'Brien, Jaehoon Lee, Seungman Kim, et al.
Depression and Anxiety|March 27, 2014
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depressionRebecca B Price, Dan V Iosifescu, James W Murrough, et al.
Pageof 19

Showing results (121-130 of 190) with videos related to

Sort By:
Pageof 19
Annals of the New York Academy of Sciences|August 8, 2006
Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrationsJeremy D Coplan, Eric L P Smith, Margaret Altemus, et al.
The Journal of Clinical Psychiatry|October 2, 2014
Ketamine safety and tolerability in clinical trials for treatment-resistant depressionLe-Ben Wan, Cara F Levitch, Andrew M Perez, et al.
Chronic Stress (Thousand Oaks, Calif.)|July 3, 2018
Early Life Stress Associated With Increased Striatal <i>N</i>-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral CorrelatesJeremy D Coplan, Dunyue Lu, Alexander M El Sehamy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2014
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trialJames W Murrough, Katherine E Burdick, Cara F Levitch, et al.
The American Journal of Psychiatry|June 25, 2019
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical TrialElias Dakwar, Edward V Nunes, Carl L Hart, et al.
Biological Psychiatry|July 31, 2012
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depressionJames W Murrough, Andrew M Perez, Sarah Pillemer, et al.
Depression and Anxiety|July 13, 2021
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trialNithya Ramakrishnan, Marijn Lijffijt, Charles E Green, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|August 28, 2024
Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-AnalysisSandesh Reddy, Katherine E Kabotyanski, Samad Hirani, et al.
Journal of Affective Disorders|October 27, 2022
Replication of distinct trajectories of antidepressant response to intravenous ketamineBrittany O'Brien, Jaehoon Lee, Seungman Kim, et al.
Depression and Anxiety|March 27, 2014
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depressionRebecca B Price, Dan V Iosifescu, James W Murrough, et al.
Pageof 19